Plasma albumin concentration is a predictor of HbA1c among type 2 diabetic patients, independently of fasting plasma glucose and fructosamine

Diabetes Care

Volumn 28, Issue 2, 2005, Pages 437-439

  Rodríguez Segade, Santiago ^a,b,c   Rodríguez, Javier ^a,b   Mayan, Dolores ^a   Camiña, Felix ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c Instituto de Salud Carlos III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; FRUCTOSAMINE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; SERUM ALBUMIN;

ALBUMIN BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FRUCTOSAMINE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN URINE LEVEL;

BLOOD GLUCOSE; CREATININE; DIABETES MELLITUS, TYPE 2; FASTING; FRUCTOSAMINE; GLOBULINS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; SERUM ALBUMIN;

EID: 12844282795     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.2.437     Document Type: Article

References (15)

1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
2. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treament and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
3. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
4. Peterson CM, Jones RL, Dupuis A, Levine BS, Bernstein R, O'Shea M: Feasibility of improved blood glucose control in patients with insulin-dependent diabetes mellitus. Diabetes Care 2:329-335, 1979
5. Nathan DM, Singer DE, Hurxthal K, Goodson JD: The clinical information value of the glycosylated Hb assay. N Engl J Med 310:341-346, 1984
6. The DCCT Research Group: Diabetes Control and Complications Trial (DCCT): results of feasibility study. Diabetes Care 10:1-19, 1987
7. 1c in the Diabetes Control and Complications Trial. Diabetes Care 25:275-278, 2002
8. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1197, 1997
9. Goldstein DE, Little RR: More than you ever wanted to know (but need to know) about glycohemoglobin testing. Diabetes Care 17:938-939, 1994
10. Abu-Lebdeh HS, Nair KS: Protein metabolism in diabetes mellitus. Baillieres Clin Endocrinol Metab 10:589-601, 1996
11. Wanke IE, Wong NC: Diabetes mellitus decreases the activity of the albumin promoter in vitro. J Biol Chem 266:6068-6072, 1991
12. Bent-Hansen L, Deckert T: Metabolism of albumin and fibrinogen in type 1 (insulin-dependent) diabetes mellitus. Diabetes Res 7:159-164, 1988
13. Jefferson LS, Liao WS, Peavy DE, Miller TB, Appel MC, Taylor JM: Diabetes-induced alterations in liver protein synthesis: changes in the relative abundance of mRNAs for albumin and other plasma proteins. J Biol Chem 258:1369-1375, 1983
14. Schnitzer JE, Bravo J: High affinity binding, endocytosis, and degradation of conformationally modified albumins: potential role of gp30 and gp18 as novel scavenger receptors. J Biol Chem 268:7562-7570, 1993
15. Morris MA, Preddy L: Glycosylation accelerates albumin degradation in normal and diabetic dogs. Biochem Med Metab Biol 35:267-270, 1986